Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis

Shyam C. Panchal; William G. Ondo

doi:10.1007/s11920-018-0869-z

Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis

Shyam C. Panchal, William G. Ondo

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Purpose of Review: We discuss features of Parkinson’s disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. Recent Findings: Pimavanserin, a 5-HT_2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment. Research into novel targets is ongoing. Summary: PDP is a morbid complication of Parkinson’s disease with complex incompletely understood mechanisms. Treatment is directed towards mitigation of psychosis without worsening of motor features.

Original language	English (US)
Article number	3
Journal	Current Psychiatry Reports
Volume	20
Issue number	1
DOIs	https://doi.org/10.1007/s11920-018-0869-z
State	Published - Jan 1 2018

Keywords

Antipsychotic
Delusions
Hallucinations
Parkinson’s disease
Pimavanserin
Psychosis

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1007/s11920-018-0869-z

Cite this

@article{14256b8f971a4b4080cd2d6e406f1ed1,

title = "Treating Hallucinations and Delusions Associated With Parkinson{\textquoteright}s Disease Psychosis",

abstract = "Purpose of Review: We discuss features of Parkinson{\textquoteright}s disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. Recent Findings: Pimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment. Research into novel targets is ongoing. Summary: PDP is a morbid complication of Parkinson{\textquoteright}s disease with complex incompletely understood mechanisms. Treatment is directed towards mitigation of psychosis without worsening of motor features.",

keywords = "Antipsychotic, Delusions, Hallucinations, Parkinson{\textquoteright}s disease, Pimavanserin, Psychosis",

author = "Panchal, {Shyam C.} and Ondo, {William G.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/s11920-018-0869-z",

language = "English (US)",

volume = "20",

journal = "Current Psychiatry Reports",

issn = "1523-3812",

publisher = "Current Science, Inc.",

number = "1",

}

TY - JOUR

T1 - Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis

AU - Panchal, Shyam C.

AU - Ondo, William G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of Review: We discuss features of Parkinson’s disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. Recent Findings: Pimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment. Research into novel targets is ongoing. Summary: PDP is a morbid complication of Parkinson’s disease with complex incompletely understood mechanisms. Treatment is directed towards mitigation of psychosis without worsening of motor features.

AB - Purpose of Review: We discuss features of Parkinson’s disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. Recent Findings: Pimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment. Research into novel targets is ongoing. Summary: PDP is a morbid complication of Parkinson’s disease with complex incompletely understood mechanisms. Treatment is directed towards mitigation of psychosis without worsening of motor features.

KW - Antipsychotic

KW - Delusions

KW - Hallucinations

KW - Parkinson’s disease

KW - Pimavanserin

KW - Psychosis

UR - http://www.scopus.com/inward/record.url?scp=85041052227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041052227&partnerID=8YFLogxK

U2 - 10.1007/s11920-018-0869-z

DO - 10.1007/s11920-018-0869-z

M3 - Review article

C2 - 29374325

AN - SCOPUS:85041052227

SN - 1523-3812

VL - 20

JO - Current Psychiatry Reports

JF - Current Psychiatry Reports

IS - 1

M1 - 3

ER -

Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this